The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | The OTHERS study: optimal duration of checkpoint inhibitors in solid tumors
Patrizia Giannatempo, MD, Foundation IRCCS National Cancer Institute, Milan, Italy, shares an overview of the OTHERS study, a systematic review and meta-analysis evaluating the optimal duration of immune checkpoint inhibitor (ICI) treatment in various solid tumors including melanoma, kidney cancer, urothelial carcinoma and lung cancer. A total of 57 randomized controlled trials involving 22,977 patients receiving ICIs were included in the analysis. The results showed that prolonged ICI treatment did not improve outcomes in patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). However, in patients with melanoma, prolonged ICI treatment was associated with better overall-survival compared to treatment for up to two years. The study highlights the need for prospective randomized trials to determine the most appropriate duration of ICI treatment for different cancer types. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
